Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Phibro Animal HealthPAHC -3.41%75 ROA % is 6.74% as of Mar. 2026, which is 10% above its 10-year median of 6.12. GuruFocus rates PAHC with a GF Score™ of 75/100 and a GF Value™ of $29.54 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 1,008 Drug Manufacturers companies, Phibro Animal Health ranks better than 71.63% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Phibro Animal Health's annualizedNet Income for the quarter that ended in Mar. 2026 was $96 Mil.
Phibro Animal Health's average Total Assets over the quarter that ended in Mar. 2026 was $1,425 Mil. Therefore, Phibro Animal Health's annualized ROA % for the quarter that ended in Mar. 2026 was 6.74%.
The historical rank and industry rank for Phibro Animal Health's ROA % or its related term are showing as below:
PAHC'
s ROA % Range Over the Past 10 Years
Min: 0.25 Med: 6.12 Max: 15.03
Current: 6.89
During the past 13 years, Phibro Animal Health's highest ROA % was 15.03%. The lowest was 0.25%. And the median was 6.12%.
PAHC's ROA % is ranked better than 71.63% of 1008
companies
in the Drug Manufacturers industry
Industry Median: 2.625
vs PAHC: 6.89
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Phibro Animal Health's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Phibro Animal Health ROA % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Phibro Animal Health's ROA % distribution charts can be found below:
* The bar in red indicates where Phibro Animal Health's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
ROA % is displayed in the 30-year financial page.
Phibro Animal Health (PAHC) has a ROA % of 6.74% as of Mar. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Phibro Animal Health and its competitors. This is 10% above median its historical median of 6.12. Over the past decade, Phibro Animal Health's ROA % has ranged from 0.25 to 15.03. According to the industry distribution chart, Phibro Animal Health ranks #286 out of 1008 companies in the Drug Manufacturers industry, placing it in the top 28.4%.
Is Phibro Animal Health's ROA % too high?
Phibro Animal Health's current ROA % of 6.74% is 10% above median its 10-year median of 6.12. Over the past 10 years, this metric has ranged from a low of 0.25 to a high of 15.03. The Drug Manufacturers industry median ROA % is 2.63. Phibro Animal Health's value of 6.74% is 156.8% above this industry median. Based on the distribution chart, Phibro Animal Health ranks #286 out of 1008 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Phibro Animal Health has a GF Score™ of 75/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Phibro Animal Health's ROA % compare to PRGO and HROW?
According to the Drug Manufacturers industry distribution chart, Phibro Animal Health ranks #286 out of 1008 companies for ROA %. This puts Phibro Animal Health in the upper half of its industry. The industry median ROA % is 2.63. Phibro Animal Health's value of 6.74% is 156.8% above this benchmark. Historically, Phibro Animal Health's own ROA % has ranged from 0.25 to 15.03 over the past decade. While the company's 10-year median is 6.12 vs. the industry median of 2.63, Phibro Animal Health has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Drug Manufacturers company?
The median ROA % among Drug Manufacturers companies is 2.63, based on 1,008 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Phibro Animal Health's current ROA % of 6.74% is 156.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Phibro Animal Health and its competitors. For the Drug Manufacturers industry, the median ROA % is 2.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Phibro Animal Health's current ROA % is 6.74%, which is 10% above median its own 10-year median of 6.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Phibro Animal Health stock overvalued right now?
Based on GuruFocus' analysis, Phibro Animal Health (PAHC) is currently considered Modestly Overvalued. The stock's GF Value™ is $29.54, compared to a current price of $34.26 — trading 16% above its estimated fair value. The current ROA % is 6.74%, which is 10% above median its 10-year median of 6.12 and 156.8% above the Drug Manufacturers industry median of 2.63. Phibro Animal Health's overall GF Score™ is 75/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Phibro Animal Health (PAHC), the current ROA % is 6.74% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Phibro Animal Health (PAHC) Overvalued in 2026?
Based on GuruFocus' analysis, Phibro Animal Health stock appears to be overvalued.
The current stock price of $34.26 is trading 16% above its estimated GF Value™ of $29.54.
GuruFocus considers Phibro Animal Health to be Modestly Overvalued.
Key valuation signals for PAHC:
ROA %: 6.74% (10% above median its 10-year median of 6.12)
GF Value™: $29.54 vs. price of $34.26 (16% above fair value)
Industry Position: 156.8% above the Drug Manufacturers median (#286 of 1008)
No single metric tells the full story. See the PAHC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Phibro Animal Health Corp operates as a diversified animal health and mineral nutrition company. It develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture. The product portfolio of the company includes animal health products such as antibacterials, anticoccidials, nutritional specialty products and vaccines, and mineral nutrition products. The company operates through three segments, Animal Health, Mineral Nutrition, and Performance Products, of which key revenue is derived from the Animal Health segment which relates to the development, manufacturing, and marketing of antibacterials, nutritional specialty products, and vaccines. The entity sells its products in the U.S. and other international countries.
75GF Score
Get the complete analysis for PAHC
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PAHC has been successfully added to your 
